A translational view of the molecular pathogenesis of lung cancer - PubMed (original) (raw)
Review
A translational view of the molecular pathogenesis of lung cancer
Mitsuo Sato et al. J Thorac Oncol. 2007 Apr.
Free article
Abstract
Molecular genetic studies of lung cancer have revealed that clinically evident lung cancers have multiple genetic and epigenetic abnormalities, including DNA sequence alterations, copy number changes, and aberrant promoter hypermethylation. Together, these abnormalities result in the activation of oncogenes and inactivation of tumor-suppressor genes. In many cases these abnormalities can be found in premalignant lesions and in histologically normal lung bronchial epithelial cells. Findings suggest that lung cancer develops through a stepwise process from normal lung epithelial cells towards frank malignancy, which usually occurs as a result of cigarette smoking. Lung cancer has a high morbidity because it is difficult to detect early and is frequently resistant to available chemotherapy and radiotherapy. New, rationally designed early detection, chemoprevention, and therapeutic strategies based on the growing understanding of the molecular changes important to lung cancer are under investigation. For example, methylated tumor DNA sequences in sputum or blood are being investigated for early detection screening, and new treatments that specifically target molecules such as vascular endothelial growth factor and the epidermal growth factor receptor are becoming available. Meanwhile, global gene expression signatures from individual tumors are showing potential as prognostic and therapeutic indicators, such that molecular typing of individual tumors for therapy selection is not far away. Finally, the recent development of a model system of immortalized human bronchial epithelial cells, along with a paradigm shift in the conception of cancer stem cells, promises to improve the situation for patients with lung cancer. These advances highlight the translation of molecular discoveries on lung cancer pathogenesis from the laboratory to the clinic.
Similar articles
- Molecular genetics of small cell lung carcinoma.
Wistuba II, Gazdar AF, Minna JD. Wistuba II, et al. Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13. Semin Oncol. 2001. PMID: 11479891 Review. - Lung cancer epigenetics and genetics.
Risch A, Plass C. Risch A, et al. Int J Cancer. 2008 Jul 1;123(1):1-7. doi: 10.1002/ijc.23605. Int J Cancer. 2008. PMID: 18425819 Review. - Molecular pathogenesis of lung cancer and potential translational applications.
Minna JD, Fong K, Zöchbauer-Müller S, Gazdar AF. Minna JD, et al. Cancer J. 2002 May-Jun;8 Suppl 1:S41-6. Cancer J. 2002. PMID: 12075701 Review. - Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA, Crowell RE. Belinsky SA, et al. Cancer Res. 2002 Apr 15;62(8):2370-7. Cancer Res. 2002. PMID: 11956099 - [Lung cancer. Epidemiology and etiologic factors].
Frusch N, Bosquée L, Louis R. Frusch N, et al. Rev Med Liege. 2007 Sep;62(9):548-53. Rev Med Liege. 2007. PMID: 17966790 French.
Cited by
- SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.
Dasgupta S, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, Das SK, Brait M, Talbot C, Yung RC, Begum S, Westra WH, Hoque MO, Yang P, Yi JE, Lam S, Gazdar AF, Fisher PB, Jen J, Sidransky D. Dasgupta S, et al. J Mol Med (Berl). 2013 Mar;91(3):381-93. doi: 10.1007/s00109-012-0955-3. Epub 2012 Sep 12. J Mol Med (Berl). 2013. PMID: 22968441 Free PMC article. - Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, Xie Y, Wistuba II, Gazdar AF, Shay JW, Minna JD. Sato M, et al. Mol Cancer Res. 2013 Jun;11(6):638-50. doi: 10.1158/1541-7786.MCR-12-0634-T. Epub 2013 Feb 28. Mol Cancer Res. 2013. PMID: 23449933 Free PMC article. - IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer.
Xu L, Cao P, Wang J, Zhang P, Hu S, Cheng C, Wang H. Xu L, et al. Heliyon. 2024 Aug 10;10(17):e35901. doi: 10.1016/j.heliyon.2024.e35901. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263114 Free PMC article. Review. - Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.
Marshall EA, Ng KW, Kung SH, Conway EM, Martinez VD, Halvorsen EC, Rowbotham DA, Vucic EA, Plumb AW, Becker-Santos DD, Enfield KS, Kennett JY, Bennewith KL, Lockwood WW, Lam S, English JC, Abraham N, Lam WL. Marshall EA, et al. Mol Cancer. 2016 Oct 27;15(1):67. doi: 10.1186/s12943-016-0551-1. Mol Cancer. 2016. PMID: 27784305 Free PMC article. Review. - Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
Yin Z, Zhou B, He Q, Li M, Guan P, Li X, Cui Z, Xue X, Su M, Ma R, Bai W, Xia S, Jiang Y, Xu S, Lv Y, Li X. Yin Z, et al. BMC Cancer. 2009 Dec 15;9:439. doi: 10.1186/1471-2407-9-439. BMC Cancer. 2009. PMID: 20003463 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials